Improving cancer treatment by enhancing a specific type of cell death during immunotherapy
Enhancing Ferroptosis to Augment Responses to Immune Checkpoint Blockade
['FUNDING_OTHER'] · VETERANS HEALTH ADMINISTRATION · NIH-11098469
This study is looking at how boosting a special kind of cell death can make cancer treatments work better for Veterans with common cancers like lung and skin cancer, by combining it with radiation therapy to help the immune system fight the tumors more effectively.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VETERANS HEALTH ADMINISTRATION (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11098469 on ClinicalTrials.gov |
What this research studies
This research investigates how enhancing a specific type of cell death, known as ferroptosis, can improve the effectiveness of immunotherapy in treating common cancers among Veterans, such as lung, colorectal, renal, and melanoma. The approach involves combining radiotherapy with immunotherapy to stimulate the immune system's response against tumors. By understanding the molecular mechanisms behind this process, the research aims to develop new treatment strategies that could lead to better outcomes for patients who currently do not benefit from existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are Veterans diagnosed with non-small cell lung cancer, colorectal cancer, renal cell carcinoma, or melanoma who are undergoing or considering immunotherapy.
Not a fit: Patients with early-stage cancers or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for Veterans, improving their chances of recovery and long-term survival.
How similar studies have performed: Previous research has shown promising results in combining radiotherapy with immunotherapy, suggesting that this approach could be effective in enhancing treatment outcomes.
Where this research is happening
ANN ARBOR, UNITED STATES
- VETERANS HEALTH ADMINISTRATION — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GREEN, MICHAEL DANIEL — VETERANS HEALTH ADMINISTRATION
- Study coordinator: GREEN, MICHAEL DANIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy